Design of the EMPERIAL-preserved trial of empagliflozin in patients with chronic heart failure with preserved ejection fraction

被引：0
|
作者：
Ponikowski, P. [1 ]
Abraham, W. T. [2 ]
Lindenfeld, J. [3 ]
Zeller, C. [4 ]
Macesic, H. [5 ]
Brueckmann, M. [6 ]
Salsali, A. [7 ]
Anker, S. D. [8 ]
机构：
[1] Wroclaw Med Univ, Wroclaw, Poland
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Charite, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P269
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [21] What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?
    Monzo, Luca
    Ferrari, Ilaria
    Cicogna, Francesco
    Tota, Claudia
    Calo, Leonardo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2022, 23 (08) : 567 - 569
  • [22] Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Zheng, Jimmy
    Parizo, Justin T.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    JAMA INTERNAL MEDICINE, 2022, 182 (12) : 1278 - 1288
  • [23] A Dose Comparison Study of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Macdonald, Blair J.
    Turgeon, Ricky D.
    CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (03) : 388 - 388
  • [24] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    HEART, 2022, 108 : A79 - A80
  • [25] Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial
    Green, Jennifer
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S25 - S25
  • [26] Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (25) : E571 - E572
  • [27] EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL
    Butler, Javed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 311 - 311
  • [28] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
  • [29] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Krawczyk, Marcin
    Mahfoud, Felix
    Haring, Bernhard
    Filippatos, Gerasimos
    Ferreira, Joao Pedro J.
    Pocock, Stuart
    Brueckmann, Martina
    Ofstad, Anne Pernille
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Packer, Milton D.
    Anker, Stefan
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
  • [30] Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
    Filippatos, Gerasimos
    Farmakis, Dimitrios
    Butler, Javed
    Zannad, Faiez
    Ferreira, Joao Pedro
    Ofstad, Anne Pernille
    Iwata, Tomoko
    Brueckmann, Martina
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 970 - 977
12345